Axial SpondyloarthritisExTASINCT04368494
Exercise Therapy in Patients With Axial Spondyloarthritis
A study testing 12-week home based exercise in people with Axial Spondyloarthritis and Inflammatory Disease, run by Loughborough University at 2 sites in United Kingdom.
Trial summary
Regular exercise, such as brisk walking, has been shown to lower levels of indicators of inflammation in the blood in people with long term conditions. This includes people with heart disease, kidney disease and diabetes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Axial Spondyloarthritis, Inflammatory Disease, Arthritis
- What is being tested?
- 12-week home based exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 1 Oct 2021to 10 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of Axial Spondyloarthritis by a consultant rheumatologist.
- Without other significant cardiovascular comorbidities.
- Receiving stable dose NSAID treatment.
- Able to commit to the time demands of the study.
Who cannot join
- Unable to undertake exercise due to physical or psychological barriers.
- Presence of hip or peripheral joint disease.
- Contraindication to exercise training (American College of Sports Medicine guidelines).
- Excessively active (score of high on International Physical Activity Questionnaire).
- Unable to communicate sufficiently in English.
- Female participants who are pregnant, lactating, or planning pregnancy during the course of the study.
Show all 9Show fewer
- Inability to give informed consent or comply with the testing and training protocol for any reason.
- Presence of chronic anaemia.
- Co-morbidity that the research team determine to be a contraindication to involvement.
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
University Hospitals of Leicester NHS trust
Leicester, LE15WW
Loughborough University, National Centre for Sport and Exercise Medicine
Loughborough, LE113TU
About this study
Official title: Exercise as an Anti-inflammatory Treatment in Axial Spondyloarthritis Patients (axSpA): a Proof of Concept Study (ExTASI).
Regular exercise, such as brisk walking, has been shown to lower levels of indicators of inflammation in the blood in people with long term conditions. This includes people with heart disease, kidney disease and diabetes. Axial Spondyloarthritis (axSpA) is an inflammatory condition with prescribed medication focusing on reducing inflammation. However, the effect of exercise on indicators of inflammation in axSpA is unknown.
The research study intends to investigate whether a 12-week period of regular exercise can have favourable effects on inflammatory markers in the blood.
Read the detailed description
Over 200,000 people in the UK have axial spondyloarthritis (axSpA). In 80% of cases the condition begins between 20-30 years of age. Exercise is encouraged as an essential treatment of axSpA, with the potential to promote well-being, flexibility, posture and pain management. Axial spondyloarthritis is an inflammatory arthritis and raised levels of indicators can be detected in the blood (e.g C-reactive protein). These markers are released as a consequence of the condition, but some, such as TNF-alpha, also promote further disease development.
In other patient groups with inflammatory diseases it has been demonstrated that regular exercise (brisk walking) can lower the levels of pro-inflammatory blood markers and increase levels of anti-inflammatory markers, independent of weight loss. Despite axSpA being an inflammatory condition with prescribed medication focused on reducing inflammation, there are no studies which have assessed the potential of exercise as an anti-inflammatory treatment in axSpA.
This research study will investigate the effect of 12 weeks of a home-based walking exercise intervention on measures of systemic inflammation and body composition. Measures of well-being and disease activity will also be investigated using established and validated methods. There will be an exercise and control group, both containing 10 participants. In the control group, patients will carry on with their normal activity. This proof-of-concept study will determine the potential of exercise as an additional anti-inflammatory treatment for patients with axSpA.
- Conditions
- Axial Spondyloarthritis, Inflammatory Disease, Arthritis
- Being tested
- 12-week home based exercise
- Keywords
- Exercise
- Medical subject headings
- Axial Spondyloarthritis, Arthritis, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
12-week home based exerciseBehavioural
Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Continue with normal activity. |
| Exercise | Experimental | 12-weeks of home based exercise involving 30 minutes of brisk walking on 5 days per week. Receives: Behavioral: 12-week home based exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in interleukin-6 blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Fasting blood concentration.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in tumor necrosis factor-alpha blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Fasting blood concentration.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in interleukin-10 blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Fasting blood concentration.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in c-reactive protein blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Fasting blood concentration.
Measured: 0, 4, 8, 12, 20 weeks.
Secondary outcomes (21)
Changes in creatine kinase blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Fasting blood concentration.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in inflammatory immune cell phenotypes before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Expression of receptors associated with inflammatory activity and stimulated cell inflammatory cytokine release. This will be analysed via flow cytometry.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in ankylosing spondylitis disease activity before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Using the validated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). The BASDAI consists of a 0-10 score (0 being no problem and 10 being the worst problem) which is used to answer 6 questions on fatigue, spinal pain, joint pain, tenderness, morning stiffness duration, and morning stiffness severity. To give each symptom equal weighting, the mean (average) of the two scores relating to stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score. The higher the score, the higher the activity of disease.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in the symptom burden of ankylosing spondylitis before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Using the validated Bath Ankylosing Spondylitis Functional Index (BASFI). The index assesses the functional limitation in patients with anykylosing spondylitis by asking the patient about symptom burden. The index consists of 10 questions evaluating how hard the patient finds situations i.e 'how difficult is it to put on your socks?' A score of 0 represents easy, and a score of 10 represents impossible. The mean (average) of the 10 questions is used to assign a symptom burden score of 0-10. The higher the score, the higher the symptom burden caused by ankylosing spondylitis.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in spinal pain before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Using the validated visual analogue scale for spinal pain. The scale consists of a straight line with the end points defining extreme limits 'no spinal pain' and 'spinal pain as bad as it could be'. The line is 10cm in length (0cm point representing no pain, 10cm point representing pain as bad as it could be). A score of 0-10 is given depending on where the patient marks the line (5cm representing a score of 5). The higher the score, the worse the spinal pain.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in overall health status before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Using the validated Assessment of SpondyloArthritis Health Index (ASAS-HI). The health index assesses health in patients with spondyloarthritis. The questionnaire asks 17 questions to assess health, with a dichotomous response option: 'I agree' and 'I do not agree'. A score of 1 is given for each 'I agree' response, and a score of 0 is given for each 'I do not agree' response. The lower the total score, the better the overall health status.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in work productivity before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Using the validated work productivity and activity impairment questionnaire (WPAI:GH). The questionnaire asks about the effect of health problems on the ability to work and perform regular activities. The questionnaire outcome is expressed as an impairment percentage, with higher numbers indicating greater impairment and less productivity.
Measured: 0, 4, 8, 12, 20 weeks.
Sedentary activity minutes per day
All participants will wear an Actigraph activity monitor on their non-dominant wrist to record physical activity for approximately 7 days (+/- 3 days) in the two weeks before the baseline assessment visit to characterise physical activity levels.
The Freedson (1998) activity monitor counts per minute cut points will be used to quantify minutes per day spent sedentary.
Measured: 7 days (+/- 3 days) in the 2 week period prior to baseline assessment.
Light physical activity minutes per day
All participants will wear an Actigraph activity monitor on their non-dominant wrist to record physical activity for approximately 7 days (+/- 3 days) in the two weeks before the baseline assessment visit to characterise physical activity levels.
The Freedson (1998) activity monitor counts per minute cut points will be used to quantify minutes per day spent in light activity.
Measured: 7 days (+/- 3 days) in the 2 week period prior to baseline assessment.
Moderate to vigorous physical activity minutes per day
All participants will wear an Actigraph activity monitor on their non-dominant wrist to record physical activity for approximately 7 days (+/- 3 days) in the two weeks before the baseline assessment visit to characterise physical activity levels.
The Freedson (1998) activity monitor counts per minute cut points will be used to quantify minutes per day spent in moderate to vigorous physical activity.
Measured: 7 days (+/- 3 days) in the 2 week period prior to baseline assessment.
Changes in subjective physical activity before (week 0 - baseline), during (week 12), and after (week 20) the 12-week home based exercise intervention.
Measured from the international physical activity questionnaire (IPAQ). The IPAQ asks 27 questions on physical activity (PA).
Those who score 'high' engage in: 1) vigorous activity on at least 3 days achieving a total PA of at least 1500 metabolic equivalent of task (MET) minutes a week - OR - 2) 7 or more days of any combination of walking, moderate intensity or vigorous intensity activities achieving a minimum total PA of at least 3000 MET minutes per week.
Those who score 'moderate' engage in: 1) 3 or more days of vigorous intensity activity and/or walking of at least 30 minutes per day - OR - 2) 5 or more days of moderate intensity activity and/or walking of at least 30 minutes per day - OR - 3) 5 or more days of any combination of walking, moderate intensity, or vigorous intensity activities achieving a minimum total PA of at least 600 MET minutes per week.
Those who score 'low' do not fit the criteria of either the moderate or high levels of PA.
Measured: 0, 12 and 20 weeks.
Changes in exercise tolerance before (week 0 - baseline), during (week 12), and after (week 20) the 12-week home based exercise intervention.
The participant will walk for 30 minutes on a motorised treadmill at a 1% gradient and at a speed that will elicit a perceived exertion of somewhat hard. The validated rating of perceiving exertion (RPE) scale will be used to quantify RPE. For the 30 minute duration, a combination of heart rate and rating of perceived exertion will be used to quantify exercise tolerance. A rating of perceived exertion of 6 represents no exertion, and a score of 20 represents maximal exertion. The score will be used to assess changes in exercise tolerance during (week 12) and after (week 20) the 12-week home based exercise intervention.
Measured: 0, 12 and 20 weeks.
Changes in physical function before (week 0 - baseline), during (week 12), and after (week 20) the 12-week home based exercise intervention.
Sit to stand-5 test.
Measured: 0, 12 and 20 weeks.
Changes in secondary physical function before (week 0 - baseline), during (week 12), and after (week 20) the 12-week home based exercise intervention.
Sit to stand-60 test.
Measured: 0, 12 and 20 weeks.
Changes in height before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Centimetres
Measured: 0, 4, 8, 12, 20 weeks.
Changes in weight before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Kilograms
Measured: 0, 4, 8, 12, 20 weeks.
Changes in waist circumference before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Centimetres
Measured: 0, 4, 8, 12, 20 weeks.
Changes in hip circumference before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Centimetres
Measured: 0, 4, 8, 12, 20 weeks.
Changes in systolic blood pressure before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
mmHg.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in diastolic blood pressure before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
mmHg.
Measured: 0, 4, 8, 12, 20 weeks.
Changes in body fat percentage before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Via tanita body composition scales (bio electrical impedance analysis).
Measured: 0, 4, 8, 12, 20 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2020
- Study start1 Oct 2021
- Primary completion10 Dec 2022
- Study completion10 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Axial SpondyloarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Random allocation into either a control group or an exercise group (12-weeks of home based exercise).
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Loughborough University
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospitals, Leicester
- Responsible party
- Principal investigator, Nicolette Bishop, Loughborough University
- Investigators
- Arumugam Moorthy, Dr, Principal investigator, University Hospitals, Leicester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04368494
- Sponsor's protocol ID
- IRAS project ID: 268333
- Acronym
- ExTASI
- Status last verified
- Mar 2023
- First submitted
- 17 Apr 2020
- Last updated
- 21 Mar 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Roberts MJ, Hamrouni M, Linsley V, Moorthy A, Bishop NC. Exercise as an anti-inflammatory Therapy in Axial Spondyloarthritis Therapeutic Intervention (EXTASI) study: a randomized controlled trial. Rheumatol Adv Pract. 2024 May 11;8(2):rkae062. doi: 10.1093/rap/rkae062. eCollection 2024.
PubMed 38854418
Study at a glance
From the registry record, last updated by the sponsor on 21 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exercise as an Anti-inflammatory Treatment in Axial Spondyloarthritis Patients (axSpA): a Proof of Concept Study (ExTASI).
- ClinicalTrials.gov ID
- NCT04368494
- Acronym / sponsor ID
- ExTASI / IRAS project ID: 268333
- Conditions
- Axial Spondyloarthritis, Inflammatory Disease, Arthritis
- Keywords
- Exercise
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Loughborough UniversityUniversity, hospital or other
- Collaborators
- University Hospitals, Leicester
- Study start
- 1 Oct 2021 (actual)
- Primary completion
- 10 Dec 2022 (actual)
- Study completion
- 10 Dec 2022 (actual)
- First posted
- 29 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Regular exercise, such as brisk walking, has been shown to lower levels of indicators of inflammation in the blood in people with long term conditions. This includes people with heart disease, kidney disease and diabetes. Axial Spondyloarthritis (axSpA) is an inflammatory condition with prescribed medication focusing on reducing inflammation. However, the effect of exercise on indicators of inflammation in axSpA is unknown.
The research study intends to investigate whether a 12-week period of regular exercise can have favourable effects on inflammatory markers in the blood.
Detailed description
Over 200,000 people in the UK have axial spondyloarthritis (axSpA). In 80% of cases the condition begins between 20-30 years of age. Exercise is encouraged as an essential treatment of axSpA, with the potential to promote well-being, flexibility, posture and pain management. Axial spondyloarthritis is an inflammatory arthritis and raised levels of indicators can be detected in the blood (e.g C-reactive protein). These markers are released as a consequence of the condition, but some, such as TNF-alpha, also promote further disease development.
In other patient groups with inflammatory diseases it has been demonstrated that regular exercise (brisk walking) can lower the levels of pro-inflammatory blood markers and increase levels of anti-inflammatory markers, independent of weight loss. Despite axSpA being an inflammatory condition with prescribed medication focused on reducing inflammation, there are no studies which have assessed the potential of exercise as an anti-inflammatory treatment in axSpA.
This research study will investigate the effect of 12 weeks of a home-based walking exercise intervention on measures of systemic inflammation and body composition. Measures of well-being and disease activity will also be investigated using established and validated methods. There will be an exercise and control group, both containing 10 participants. In the control group, patients will carry on with their normal activity. This proof-of-concept study will determine the potential of exercise as an additional anti-inflammatory treatment for patients with axSpA.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Random allocation into either a control group or an exercise group (12-weeks of home based exercise).
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Continue with normal activity. |
| Exercise | Experimental | Behavioral: 12-week home based exercise12-weeks of home based exercise involving 30 minutes of brisk walking on 5 days per week. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of Axial Spondyloarthritis by a consultant rheumatologist.
- Without other significant cardiovascular comorbidities.
- Receiving stable dose NSAID treatment.
- Able to commit to the time demands of the study.
Key exclusion criteria (9 listed)
- Unable to undertake exercise due to physical or psychological barriers.
- Presence of hip or peripheral joint disease.
- Contraindication to exercise training (American College of Sports Medicine guidelines).
- Excessively active (score of high on International Physical Activity Questionnaire).
- Unable to communicate sufficiently in English.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 12-week home based exercisePatients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration. | Behavioural | Exercise |
Primary outcome
Changes in interleukin-6 blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Fasting blood concentration.
Changes in tumor necrosis factor-alpha blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Fasting blood concentration.
Changes in interleukin-10 blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Fasting blood concentration.
Changes in c-reactive protein blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Fasting blood concentration.
21 secondary outcomes
Changes in creatine kinase blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in inflammatory immune cell phenotypes before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in ankylosing spondylitis disease activity before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in the symptom burden of ankylosing spondylitis before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in spinal pain before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in overall health status before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in work productivity before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Sedentary activity minutes per day
Time frame: 7 days (+/- 3 days) in the 2 week period prior to baseline assessment.
Light physical activity minutes per day
Time frame: 7 days (+/- 3 days) in the 2 week period prior to baseline assessment.
Moderate to vigorous physical activity minutes per day
Time frame: 7 days (+/- 3 days) in the 2 week period prior to baseline assessment.
Changes in subjective physical activity before (week 0 - baseline), during (week 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 12 and 20 weeks.
Changes in exercise tolerance before (week 0 - baseline), during (week 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 12 and 20 weeks.
Changes in physical function before (week 0 - baseline), during (week 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 12 and 20 weeks.
Changes in secondary physical function before (week 0 - baseline), during (week 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 12 and 20 weeks.
Changes in height before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in weight before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in waist circumference before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in hip circumference before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in systolic blood pressure before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in diastolic blood pressure before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Changes in body fat percentage before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention.
Time frame: 0, 4, 8, 12, 20 weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Mar 2023.
- Derived from this study: PubMed 38854418Roberts MJ, Hamrouni M, Linsley V, Moorthy A, Bishop NC. Exercise as an anti-inflammatory Therapy in Axial Spondyloarthritis Therapeutic Intervention (EXTASI) study: a randomized controlled trial. Rheumatol Adv Pract. 2024 May 11;8(2):rkae062. doi: 10.1093/rap/rkae062. eCollection 2024.
- Individual participant dataSharing planned: No
Related trials for Axial Spondyloarthritis
Active, not recruiting
Effects of Resistance Exercise on Enthesitis in Patients With Spondyloarthritis
Spondyloarthritis (SpA), Axial Spondylarthritis (axSpA)
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Psoriatic Arthritis, Axial Spondyloarthritis
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
Identification of Serum Level of Glutathione Peroxidase 4
Spondyloarthropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arumugam Moorthy, Dr principal investigator
University Hospitals, Leicester
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 12-week home based exercise in people with Axial Spondyloarthritis and Inflammatory Disease, run by Loughborough University at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in interleukin-6 blood concentrations before (week 0 - baseline), during (weeks 4, 8, and 12), and after (week 20) the 12-week home based exercise intervention. (time frame: 0, 4, 8, 12, 20 weeks.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04368494, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2023.